Keyphrases
Rituximab
100%
Phase II Trial
100%
Lenalidomide
100%
International Prognostic Index
100%
Previously Untreated
100%
Follicular non-Hodgkin Lymphoma
100%
Follicular Lymphoma
80%
Polymorphism
40%
Rash
40%
Bulky Disease
40%
Confidence Interval
20%
Patient-completed
20%
Response Rate
20%
Progression-free Survival
20%
Adverse Events
20%
Overall Response Rate
20%
Diarrhea
20%
Neutropenia
20%
Low Dose Rate
20%
Chemotherapy
20%
5-year Survival
20%
Hematopoietic Stem Cells
20%
Hematotoxicity
20%
Histological Grade
20%
Tolerability
20%
Lymphopenia
20%
Time to Progression
20%
Febrile Neutropenia
20%
Immunochemotherapy
20%
2′-fucosyllactose (2′-FL)
20%
Circulating Endothelial Cells
20%
25Mg
20%
Reasons for Discontinuation
20%
Toxicity Response
20%
Proangiogenic Cells
20%
Thrombocytopenia 2
20%
Pharmacology, Toxicology and Pharmaceutical Science
Nonhodgkin Lymphoma
100%
Rituximab
100%
Phase II Trials
100%
Lenalidomide
100%
Follicular Lymphoma
80%
Rash
40%
Diseases
40%
Infection
20%
Progression Free Survival
20%
Diarrhea
20%
Neutropenia
20%
Adverse Event
20%
Overall Survival
20%
Chemotherapy
20%
Thrombocytopenia
20%
Tolerability
20%
Febrile Neutropenia
20%
Lymphocytopenia
20%